THROMBOTARGETS CORPORATION module listen to the incoming 13th ANNUAL INTERNATIONAL PARTNERING CONFERENCE Bio-Europe 2007 that it module verify locate in Hamburg, Germany, November 12-14, 2007. It is the most direct Annual International Convention in Biotechnology in Europe.

Thrombotargets key strategic content is to advise to enhance and amend our creation scuttlebutt as substantially as out-license our HTS platforms. This strategy provides to the partners coercive verify candidates and it strengthens our function as a directive biotech consort in Thrombosis and Hemostasia areas. ABOUT THROMBOTARGETS GROUP

Thrombotargets (www.thrombotargets.com) is a privately held assemble of Biotech companies convergent on the brainstorm and utilization of warning drugs in Haemostasis, Thrombosis and Atherosclerosis. Thrombotargets Corporation (N. Carolina, USA) is answerable for Drug Development and High Throughput Screening; Thrombotargets aggregation (Barcelona, Spain) for Target Identification, Lead determination and Lead improvement and Biotech Libraries for engineered targeted libraries.

Thrombotargets assemble is creating a continuously ontogeny and warning pipeline.

Presently, digit of most warning verify candidates, TT-103MH, a newborn antihemorrhagic manlike recombinant accelerator to be ingest topically, and TT-105, a newborn anticoagulant monoclonal antibody in pre clinical phase. Thrombotargets module advise Phase I try with TT-103 in Q1 2008, and has conventional the Orphan Drug Designation to the bureau for TT-103 MH in Feb 2007. TT-111 and TT-112 are digit warning antifibrinolytic compounds, having higher potency than underway advertizement antifibrinolytic drugs, which are existence matured in collaboration with Asinex, Russia.